1z92 › Citations

The structure of interleukin-2 complexed with its alpha receptor.

Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC
Science 308 1477-80 (2005)
Cited: 143 times
EuropePMC logo PMID: 15933202

Reviews - 1z92 mentioned but not cited (5)

  1. Understanding protein non-folding. Uversky VN, Dunker AK. Biochim. Biophys. Acta 1804 1231-1264 (2010)
  2. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Arkin MR, Tang Y, Wells JA. Chem. Biol. 21 1102-1114 (2014)
  3. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Smith MC, Gestwicki JE. Expert Rev Mol Med 14 e16 (2012)
  4. The design and development of covalent protein-protein interaction inhibitors for cancer treatment. Cheng SS, Yang GJ, Wang W, Leung CH, Ma DL. J Hematol Oncol 13 26 (2020)
  5. In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Shin WH, Christoffer CW, Kihara D. Methods 131 22-32 (2017)

Articles - 1z92 mentioned but not cited (35)

  1. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC. Nature 484 529-533 (2012)
  2. Quantifying Correlations Between Allosteric Sites in Thermodynamic Ensembles. McClendon CL, Friedland G, Mobley DL, Amirkhani H, Jacobson MP. J Chem Theory Comput 5 2486-2502 (2009)
  3. Hot-spot mimicry of a cytokine receptor by a small molecule. Thanos CD, DeLano WL, Wells JA. Proc. Natl. Acad. Sci. U.S.A. 103 15422-15427 (2006)
  4. HotPoint: hot spot prediction server for protein interfaces. Tuncbag N, Keskin O, Gursoy A. Nucleic Acids Res. 38 W402-6 (2010)
  5. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. Bourgeas R, Basse MJ, Morelli X, Roche P. PLoS One 5 e9598 (2010)
  6. Identification of hot-spot residues in protein-protein interactions by computational docking. Grosdidier S, Fernández-Recio J. BMC Bioinformatics 9 447 (2008)
  7. Electrostatic properties of protein-protein complexes. Kundrotas PJ, Alexov E. Biophys. J. 91 1724-1736 (2006)
  8. DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions. Krüger DM, Gohlke H. Nucleic Acids Res. 38 W480-6 (2010)
  9. Binding-site assessment by virtual fragment screening. Huang N, Jacobson MP. PLoS One 5 e10109 (2010)
  10. Alignment of non-covalent interactions at protein-protein interfaces. Zhu H, Sommer I, Lengauer T, Domingues FS. PLoS ONE 3 e1926 (2008)
  11. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. Lopes JE, Fisher JL, Flick HL, Wang C, Sun L, Ernstoff MS, Alvarez JC, Losey HC. J Immunother Cancer 8 e000673 (2020)
  12. Balancing target flexibility and target denaturation in computational fragment-based inhibitor discovery. Foster TJ, MacKerell AD, Guvench O. J Comput Chem 33 1880-1891 (2012)
  13. Modulating protein-protein interactions with small molecules: the importance of binding hotspots. Thangudu RR, Bryant SH, Panchenko AR, Madej T. J. Mol. Biol. 415 443-453 (2012)
  14. HADDOCK(2P2I): a biophysical model for predicting the binding affinity of protein-protein interaction inhibitors. Kastritis PL, Rodrigues JP, Bonvin AM. J Chem Inf Model 54 826-836 (2014)
  15. Tetrandrine inhibits colon carcinoma HT-29 cells growth via the Bcl-2/Caspase 3/PARP pathway and G1/S phase. Li J, Wang Q, Wang Z, Cui N, Yang B, Niu W, Kuang H. Biosci Rep 39 BSR20182109 (2019)
  16. Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. Loving KA, Lin A, Cheng AC. PLoS Comput Biol 10 e1003741 (2014)
  17. What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics? Higueruelo AP, Schreyer A, Bickerton GR, Blundell TL, Pitt WR. PLoS ONE 7 e51742 (2012)
  18. 2P2Idb v2: update of a structural database dedicated to orthosteric modulation of protein-protein interactions. Basse MJ, Betzi S, Morelli X, Roche P. Database (Oxford) 2016 (2016)
  19. Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15Rα. Dijkstra JM, Takizawa F, Fischer U, Friedrich M, Soto-Lampe V, Lefèvre C, Lenk M, Karger A, Matsui T, Hashimoto K. Immunogenetics 66 93-103 (2014)
  20. Visualisation of variable binding pockets on protein surfaces by probabilistic analysis of related structure sets. Ashford P, Moss DS, Alex A, Yeap SK, Povia A, Nobeli I, Williams MA. BMC Bioinformatics 13 39 (2012)
  21. Helicobacter pylori neutrophil-activating protein: a potential Treg modulator suppressing allergic asthma? Sehrawat A, Sinha S, Saxena A. Front Microbiol 6 493 (2015)
  22. Computational alanine scanning with linear scaling semiempirical quantum mechanical methods. Diller DJ, Humblet C, Zhang X, Westerhoff LM. Proteins 78 2329-2337 (2010)
  23. Engineering a Single-Agent Cytokine/Antibody Fusion That Selectively Expands Regulatory T Cells for Autoimmune Disease Therapy. Spangler JB, Trotta E, Tomala J, Peck A, Young TA, Savvides CS, Silveria S, Votavova P, Salafsky J, Pande VS, Kovar M, Bluestone JA, Garcia KC. J. Immunol. 201 2094-2106 (2018)
  24. Docking-based identification of small-molecule binding sites at protein-protein interfaces. Rosell M, Fernández-Recio J. Comput Struct Biotechnol J 18 3750-3761 (2020)
  25. Fractal Dimensions of Macromolecular Structures. Todoroff N, Kunze J, Schreuder H, Hessler G, Baringhaus KH, Schneider G. Mol Inform 33 588-596 (2014)
  26. Systematically Deciphering the Pharmacological Mechanism of Fructus Aurantii via Network Pharmacology. Jin Q, Lu J, Gao R, Xu J, Pan X, Wang L. Evid Based Complement Alternat Med 2021 6236135 (2021)
  27. p-TSA-promoted syntheses of 5H-benzo[h] thiazolo[2,3-b]quinazoline and indeno[1,2-d] thiazolo[3,2-a]pyrimidine analogs: molecular modeling and in vitro antitumor activity against hepatocellular carcinoma. Keshari AK, Singh AK, Raj V, Rai A, Trivedi P, Ghosh B, Kumar U, Rawat A, Kumar D, Saha S. Drug Des Devel Ther 11 1623-1642 (2017)
  28. Crystal structure of human interleukin-2 in complex with TCB2, a new antibody-drug candidate with antitumor activity. Kim J, Lee JY, Park SY, Lee YJ, Kim MS. Oncoimmunology 10 1899671 (2021)
  29. Indole-fused benzooxazepines: a new structural class of anticancer agents. Singh AK, Raj V, Rai A, Keshari AK, Saha S. Future Sci OA 3 FSO168 (2017)
  30. A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers. Dehbashi M, Hojati Z, Motovali-Bashi M, Ganjalikhany MR, Cho WC, Shimosaka A, Navabi P, Ganjalikhani-Hakemi M. Front Oncol 11 649710 (2021)
  31. An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein Interfaces. Nakadai M, Tomida S, Sekimizu K. Sci Rep 6 18543 (2016)
  32. An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination. Zhang HQ, Cao BZ, Cao QT, Hun M, Cao L, Zhao MY. Hum Vaccin Immunother 19 2263229 (2023)
  33. Computational Simulations Highlight the IL2Rα Binding Potential of Polyphenol Stilbenes from Fenugreek. Kulkarni AM, Parate S, Lee G, Kim Y, Jung TS, Lee KW, Ha MW. Molecules 27 1215 (2022)
  34. Correction to: The design and development of covalent protein-protein interaction inhibitors for cancer treatment. Cheng SS, Yang GJ, Wang W, Leung CH, Ma DL. J Hematol Oncol 13 102 (2020)
  35. Improving de novo protein binder design with deep learning. Bennett NR, Coventry B, Goreshnik I, Huang B, Allen A, Vafeados D, Peng YP, Dauparas J, Baek M, Stewart L, DiMaio F, De Munck S, Savvides SN, Baker D. Nat Commun 14 2625 (2023)


Reviews citing this publication (45)

  1. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Wells JA, McClendon CL. Nature 450 1001-1009 (2007)
  2. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Uversky VN, Oldfield CJ, Dunker AK. Annu Rev Biophys 37 215-246 (2008)
  3. Effector and memory CTL differentiation. Williams MA, Bevan MJ. Annu. Rev. Immunol. 25 171-192 (2007)
  4. The biology of interleukin-2. Malek TR. Annu. Rev. Immunol. 26 453-479 (2008)
  5. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Ma A, Koka R, Burkett P. Annu. Rev. Immunol. 24 657-679 (2006)
  6. Structural biology of shared cytokine receptors. Wang X, Lupardus P, Laporte SL, Garcia KC. Annu. Rev. Immunol. 27 29-60 (2009)
  7. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Scott DE, Bayly AR, Abell C, Skidmore J. Nat Rev Drug Discov 15 533-550 (2016)
  8. An overview of enzymatic reagents for the removal of affinity tags. Waugh DS. Protein Expr. Purif. 80 283-293 (2011)
  9. Oncogenic protein interfaces: small molecules, big challenges. Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Nat. Rev. Cancer 14 248-262 (2014)
  10. Protein-protein interactions as targets for small molecule drug discovery. Fry DC. Biopolymers 84 535-552 (2006)
  11. Daclizumab therapy for multiple sclerosis. Bielekova B. Neurotherapeutics 10 55-67 (2013)
  12. The IL-2 cytokine family in cancer immunotherapy. Sim GC, Radvanyi L. Cytokine Growth Factor Rev. 25 377-390 (2014)
  13. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Zeiser R, Negrin RS. Cell Cycle 7 458-462 (2008)
  14. Role of IL-2 in cancer immunotherapy. Jiang T, Zhou C, Ren S. Oncoimmunology 5 e1163462 (2016)
  15. A biophysical approach to IL-2 and IL-15 receptor function: localization, conformation and interactions. Bodnár A, Nizsalóczki E, Mocsár G, Szalóki N, Waldmann TA, Damjanovich S, Vámosi G. Immunol. Lett. 116 117-125 (2008)
  16. Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions. Schön A, Lam SY, Freire E. Future Med Chem 3 1129-1137 (2011)
  17. Developmental and Functional Control of Natural Killer Cells by Cytokines. Wu Y, Tian Z, Wei H. Front Immunol 8 930 (2017)
  18. What makes a good anti-inflammatory drug target? Simmons DL. Drug Discov. Today 11 210-219 (2006)
  19. A molecular perspective on TH2-promoting cytokine receptors in patients with allergic disease. Romeo MJ, Agrawal R, Pomés A, Woodfolk JA. J. Allergy Clin. Immunol. 133 952-960 (2014)
  20. Deciphering complement mechanisms: the contributions of structural biology. Arlaud GJ, Barlow PN, Gaboriaud C, Gros P, Narayana SV. Mol. Immunol. 44 3809-3822 (2007)
  21. Multifarious determinants of cytokine receptor signaling specificity. Moraga I, Spangler J, Mendoza JL, Garcia KC. Adv. Immunol. 121 1-39 (2014)
  22. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera. Votavova P, Tomala J, Kovar M. Immunol. Lett. 159 1-10 (2014)
  23. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Setrerrahmane S, Xu H. Mol. Cancer 16 153 (2017)
  24. Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. Ballesteros-Tato A. Immunotherapy 6 1207-1220 (2014)
  25. The Common Cytokine Receptor γ Chain Family of Cytokines. Lin JX, Leonard WJ. Cold Spring Harb Perspect Biol 10 (2018)
  26. Transcriptional Regulation of NK Cell Development by mTOR Complexes. Yang C, Malarkannan S. Front Cell Dev Biol 8 566090 (2020)
  27. Revisiting IL-2: Biology and therapeutic prospects. Abbas AK, Trotta E, R Simeonov D, Marson A, Bluestone JA. Sci Immunol 3 (2018)
  28. The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer. Flynn MJ, Hartley JA. Br. J. Haematol. 179 20-35 (2017)
  29. Chemical modulators working at pharmacological interface of target proteins. Jeon YH, Lee JY, Kim S. Bioorg. Med. Chem. 20 1893-1901 (2012)
  30. Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. Mussafi O, Mei J, Mao W, Wan Y. Front Oncol 12 948405 (2022)
  31. Prospects of IL-2 in Cancer Immunotherapy. Choudhry H, Helmi N, Abdulaal WH, Zeyadi M, Zamzami MA, Wu W, Mahmoud MM, Warsi MK, Rasool M, Jamal MS. Biomed Res Int 2018 9056173 (2018)
  32. Daclizumab Therapy for Multiple Sclerosis. Bielekova B. Cold Spring Harb Perspect Med 9 (2019)
  33. Implications of a 'Third Signal' in NK Cells. Khalil M, Wang D, Hashemi E, Terhune SS, Malarkannan S. Cells 10 1955 (2021)
  34. Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Patti F, Chisari CG, D'Amico E, Zappia M. Expert Opin Drug Metab Toxicol 14 341-352 (2018)
  35. The Potential of Harnessing IL-2-Mediated Immunosuppression to Prevent Pathogenic B Cell Responses. Papillion A, Ballesteros-Tato A. Front Immunol 12 667342 (2021)
  36. "IL-2 immunotherapy for targeting regulatory T cells in autoimmunity". Lykhopiy V, Malviya V, Humblet-Baron S, Schlenner SM. Genes Immun 24 248-262 (2023)
  37. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. Habanjar O, Bingula R, Decombat C, Diab-Assaf M, Caldefie-Chezet F, Delort L. Int J Mol Sci 24 4002 (2023)
  38. Emerging principles of cytokine pharmacology and therapeutics. Saxton RA, Glassman CR, Garcia KC. Nat Rev Drug Discov 22 21-37 (2023)
  39. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Hernandez R, Põder J, LaPorte KM, Malek TR. Nat Rev Immunol (2022)
  40. Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Protein-Protein Interactions: An Update. Wu X, Zhang Q, Guo Y, Zhang H, Guo X, You Q, Wang L. Antioxidants (Basel) 11 619 (2022)
  41. Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Accogli T, Bruchard M, Végran F. Cancers (Basel) 13 (2021)
  42. Strategies to therapeutically modulate cytokine action. Leonard WJ, Lin JX. Nat Rev Drug Discov (2023)
  43. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11. Metcalfe RD, Putoczki TL, Griffin MDW. Front Immunol 11 1424 (2020)
  44. The cytokine network involved in the host immune response to periodontitis. Pan W, Wang Q, Chen Q. Int J Oral Sci 11 30 (2019)
  45. The potential of regulatory T cell-based therapies for alopecia areata. Wan S, Xu W, Xie B, Guan C, Song X. Front Immunol 14 1111547 (2023)

Articles citing this publication (58)

  1. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Cell 132 259-272 (2008)
  2. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. J. Exp. Med. 205 1213-1225 (2008)
  3. Identification of CD25+ gamma delta T cells as fetal thymus-derived naturally occurring IL-17 producers. Shibata K, Yamada H, Nakamura R, Sun X, Itsumi M, Yoshikai Y. J Immunol 181 5940-5947 (2008)
  4. Structural conservation of druggable hot spots in protein-protein interfaces. Kozakov D, Hall DR, Chuang GY, Cencic R, Brenke R, Grove LE, Beglov D, Pelletier J, Whitty A, Vajda S. Proc. Natl. Acad. Sci. U.S.A. 108 13528-13533 (2011)
  5. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 103 2788-2793 (2006)
  6. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R, Ozkan E, Leonard WJ, Garcia KC. Nat. Immunol. 13 1187-1195 (2012)
  7. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, Csako G, Bielekova B. Sci Transl Med 4 145ra106 (2012)
  8. IL-2Rbeta links IL-2R signaling with Foxp3 expression. Soper DM, Kasprowicz DJ, Ziegler SF. Eur. J. Immunol. 37 1817-1826 (2007)
  9. Crystal Structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation. Olsen SK, Ota N, Kishishita S, Kukimoto-Niino M, Murayama K, Uchiyama H, Toyama M, Terada T, Shirouzu M, Kanagawa O, Yokoyama S. J Biol Chem 282 37191-37204 (2007)
  10. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Mitra S, Ring AM, Amarnath S, Spangler JB, Li P, Ju W, Fischer S, Oh J, Spolski R, Weiskopf K, Kohrt H, Foley JE, Rajagopalan S, Long EO, Fowler DH, Waldmann TA, Garcia KC, Leonard WJ. Immunity 42 826-838 (2015)
  11. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. Lupardus PJ, Garcia KC. J. Mol. Biol. 382 931-941 (2008)
  12. Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans. Chirifu M, Hayashi C, Nakamura T, Toma S, Shuto T, Kai H, Yamagata Y, Davis SJ, Ikemizu S. Nat. Immunol. 8 1001-1007 (2007)
  13. The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. Dendrou CA, Wicker LS. J. Clin. Immunol. 28 685-696 (2008)
  14. The structure of the interleukin-15 alpha receptor and its implications for ligand binding. Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J. J Biol Chem 281 6642-6647 (2006)
  15. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A. J. Mol. Biol. 382 1-12 (2008)
  16. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J. Cancer Immunol. Immunother. 60 1789-1800 (2011)
  17. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Oncoimmunology 6 e1277306 (2017)
  18. IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Tamzalit F, Barbieux I, Plet A, Heim J, Nedellec S, Morisseau S, Jacques Y, Mortier E. Proc. Natl. Acad. Sci. U.S.A. 111 8565-8570 (2014)
  19. Discovery of small-molecule interleukin-2 inhibitors from a DNA-encoded chemical library. Leimbacher M, Zhang Y, Mannocci L, Stravs M, Geppert T, Scheuermann J, Schneider G, Neri D. Chemistry 18 7729-7737 (2012)
  20. IL-2 receptor beta-chain signaling controls immunosuppressive CD4+ T cells in the draining lymph nodes and lung during allergic airway inflammation in vivo. Doganci A, Karwot R, Maxeiner JH, Scholtes P, Schmitt E, Neurath MF, Lehr HA, Ho IC, Finotto S. J Immunol 181 1917-1926 (2008)
  21. The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, Worsaae A, Becker P, Schiødt CB, Hjorth SA. J Biol Chem 282 23326-23336 (2007)
  22. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O. Sci Transl Med 8 367ra166 (2016)
  23. Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H. Makou E, Mertens HD, Maciejewski M, Soares DC, Matis I, Schmidt CQ, Herbert AP, Svergun DI, Barlow PN. J. Mol. Biol. 424 295-312 (2012)
  24. The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs. Smith KA. Med Immunol 5 3 (2006)
  25. Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis. Liu Y, Schön A, Freire E. Chem Biol Drug Des 81 72-78 (2013)
  26. Structural properties of non-traditional drug targets present new challenges for virtual screening. Gowthaman R, Deeds EJ, Karanicolas J. J Chem Inf Model 53 2073-2081 (2013)
  27. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. Du J, Yang H, Zhang D, Wang J, Guo H, Peng B, Guo Y, Ding J. J Immunol 184 1361-1368 (2010)
  28. Structural basis of immunosuppression by the therapeutic antibody daclizumab. Yang H, Wang J, Du J, Zhong C, Zhang D, Guo H, Guo Y, Ding J. Cell Res. 20 1361-1371 (2010)
  29. Contributions of interfacial residues of human Interleukin15 to the specificity and affinity for its private alpha-receptor. Sakamoto S, Caaveiro JM, Sano E, Tanaka Y, Kudou M, Tsumoto K. J. Mol. Biol. 389 880-894 (2009)
  30. PRICE (PRotein Interface Conservation and Energetics): a server for the analysis of protein-protein interfaces. Guharoy M, Pal A, Dasgupta M, Chakrabarti P. J. Struct. Funct. Genomics 12 33-41 (2011)
  31. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Trotta E, Bessette PH, Silveria SL, Ely LK, Jude KM, Le DT, Holst CR, Coyle A, Potempa M, Lanier LL, Garcia KC, Crellin NK, Rondon IJ, Bluestone JA. Nat. Med. 24 1005-1014 (2018)
  32. Dimerization of Kit-ligand and efficient cell-surface presentation requires a conserved Ser-Gly-Gly-Tyr motif in its transmembrane domain. Paulhe F, Wehrle-Haller M, Jacquier MC, Imhof BA, Tabone-Eglinger S, Wehrle-Haller B. FASEB J. 23 3037-3048 (2009)
  33. Tissue distribution and functional analysis of Sushi domain-containing protein 4. Tu Z, Cohen M, Bu H, Lin F. Am. J. Pathol. 176 2378-2384 (2010)
  34. Alternative Splicing Rescues Loss of Common Gamma Chain Function and Results in IL-21R-like Deficiency. Illig D, Navratil M, Kelečić J, Conca R, Hojsak I, Jadrešin O, Ćorić M, Vuković J, Rohlfs M, Hollizeck S, Bohne J, Klein C, Kotlarz D. J Clin Immunol 39 207-215 (2019)
  35. Docking of human interleukin-15 to its specific receptor alpha chain: correlation between molecular modeling and mutagenesis experimental data. Quéméner A, Bernard J, Mortier E, Plet A, Jacques Y, Tran V. Proteins 65 623-636 (2006)
  36. Structural determinants of interaction, trafficking and function in the ClC-2/MLC1 subunit GlialCAM involved in leukodystrophy. Capdevila-Nortes X, Jeworutzki E, Elorza-Vidal X, Barrallo-Gimeno A, Pusch M, Estévez R. J. Physiol. (Lond.) 593 4165-4180 (2015)
  37. Structure and Function of an Inflammatory Cytokine, Interleukin-2, Analyzed Using the Bioinformatic Approach. Roy U. Protein J 38 525-536 (2019)
  38. The protein-protein interface evolution acts in a similar way to antibody affinity maturation. Li B, Zhao L, Wang C, Guo H, Wu L, Zhang X, Qian W, Wang H, Guo Y. J. Biol. Chem. 285 3865-3871 (2010)
  39. A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. Volkland J, Lumsden J, Mølhøj M, Raum T, Hausmann S, Wissing S, Wissinger M, Hoffmann P, Sriskandarajah M, Kvesic M, Baeuerle PA, Pflanz S. Mol. Immunol. 44 1743-1753 (2007)
  40. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Pescovitz MD. Expert Rev Clin Immunol 1 337-344 (2005)
  41. Identification of small molecule inhibitors of Interleukin-18. Krumm B, Meng X, Xiang Y, Deng J. Sci Rep 7 483 (2017)
  42. Intermodule cooperativity in the structure and dynamics of consecutive complement control modules in human C1r: structural biology. Láng A, Szilágyi K, Major B, Gál P, Závodszky P, Perczel A. FEBS J. 277 3986-3998 (2010)
  43. An analysis of early-stage IL-2 capture times in populations of T cells diffusively interacting in a confined environment. Labowsky M. J. Theor. Biol. 411 37-47 (2016)
  44. High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model. Pink D, Luhrs KA, Zhou L, Schulte W, Chase J, Frosch C, Haberl U, Nguyen V, Roy AI, Lewis JD, Zijlstra A, Parseghian MH. Sci Rep 5 15756 (2015)
  45. Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells. Terrén I, Mikelez I, Odriozola I, Gredilla A, González J, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F. Front Immunol 9 737 (2018)
  46. TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity. Lee JY, Lee E, Hong SW, Kim D, Eunju O, Sprent J, Im SH, Lee YJ, Surh CD. Oncoimmunology 9 1681869 (2020)
  47. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Harris KE, Lorentsen KJ, Malik-Chaudhry HK, Loughlin K, Basappa HM, Hartstein S, Ahmil G, Allen NS, Avanzino BC, Balasubramani A, Boudreau AA, Chang K, Cuturi MC, Davison LM, Ho DM, Iyer S, Rangaswamy US, Sankaran P, Schellenberger U, Buelow R, Trinklein ND. Sci Rep 11 10592 (2021)
  48. Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome. Gambineri E, Ciullini Mannurita S, Hagin D, Vignoli M, Anover-Sombke S, DeBoer S, Segundo GRS, Allenspach EJ, Favre C, Ochs HD, Torgerson TR. Front Immunol 9 2411 (2018)
  49. Case Reports Granulomatous hepatitis in a Saudi child with IL2RA defect: a case report and literature review. Alaifan MA, Abusharifah O, Bokhary RY, Banaganapalli B, Shaik NA, Kamal NM, Saadah OI. Ther Adv Chronic Dis 13 20406223221116798 (2022)
  50. How does a small molecule bind at a cryptic binding site? Shan Y, Mysore VP, Leffler AE, Kim ET, Sagawa S, Shaw DE. PLoS Comput Biol 18 e1009817 (2022)
  51. Identification of potent anti-immunogenic agents through virtual screening, 3D-QSAR studies, and in vitro experiments. Mushtaq M, Usmani S, Jabeen A, Nur-E-Alam M, Ahmed S, Ahmad A, Ul-Haq Z. Mol Divers (2023)
  52. Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides. Price-Troska T, Yang ZZ, Diller D, Bayden A, Jarosinski M, Audie J, Ansell SM. Invest New Drugs 37 9-16 (2019)
  53. Properties that rank protein:protein docking poses with high accuracy. Simões ICM, Coimbra JTS, Neves RPP, Costa IPD, Ramos MJ, Fernandes PA. Phys Chem Chem Phys 20 20927-20942 (2018)
  54. SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling. Zhao B, Gong W, Ma A, Chen J, Velegraki M, Dong H, Liu Z, Wang L, Okimoto T, Jones DM, Lei YL, Long M, Oestreich KJ, Ma Q, Xin G, Carbone DP, He K, Li Z, Wen H. Nat Immunol 23 1588-1599 (2022)
  55. Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice. Lee E, Kim M, Lee YJ. Front Immunol 13 874778 (2022)
  56. Structural and functional characterisation of ferret interleukin-2. Ren B, McKinstry WJ, Pham T, Newman J, Layton DS, Bean AG, Chen Z, Laurie KL, Borg K, Barr IG, Adams TE. Dev Comp Immunol 55 32-38 (2016)
  57. Tethering IL2 to Its Receptor IL2Rβ Enhances Antitumor Activity and Expansion of Natural Killer NK92 Cells. Jounaidi Y, Cotten JF, Miller KW, Forman SA. Cancer Res. 77 5938-5951 (2017)
  58. [IL-2-receptor associated action of the modified peptide fragments of human IL-2 on macrophages]. Onoprienko LV, Mikhaleva II, Voĭtenkov BO, Ivanov VT. Bioorg. Khim. 38 413-420 (2012)


Quick links